Toll-like receptor 2 in serum: a potential diagnostic marker of prosthetic joint infection? by E. Galliera et al.
Toll-Like Receptor 2 in Serum: a Potential Diagnostic Marker of
Prosthetic Joint Infection?
Emanuela Galliera,a,b Lorenzo Drago,b,c Christian Vassena,b Carlo Romanò,b Monica Gioia Marazzi,c Lucia Salcito,c
Massimiliano M. Corsi Romanellic,d
Department of Biomedical, Surgical and Oral Science, Università degli Studi di Milano, Milan, Italya; IRCCS Galeazzi Orthopaedic Institute, Milan, Italyb; Department of
Biomedical Science for Health, Università degli Studi di Milano, Milan, Italyc; IRCCS Policlinico San Donato, San Donato (Milan), Italyd
Prosthetic joint infection (PJI) is a severe complication of arthroplasty and is still lacking diagnostic gold standards. PJI patients
display high Toll-like receptor 2 (TLR2) serum levels, correlating with canonical inflammatory markers (C-reactive protein
[CRP], interleukin 6 [IL-6], tumor necrosis factor alpha [TNF-], and IL-1). Therefore, TLR2 serum levels could be considered a
new potential diagnostic tool in the early detection of PJI.
Toll-like receptor (TLR) represents the first line of defenseagainst invading pathogens (1) by recognizing the invading
bacteria and activating the inflammatory response aimed to elim-
inate the pathogen and repair the damaged tissue. Among TLRs,
TLR4 andTLR2 recognize a broad spectrumofGram-positive and
Gram-negative bacteria, respectively, and induce the main in-
flammatory response (2, 3). Periprosthetic joint infection (PJI)
(4–8) is one of the main adverse events of orthopedic surgical
procedures (9–11). Currently, a large number of tests are available
for PJI diagnosis, ranging from hematological markers of infec-
tion and inflammation to intraoperative culture and histology
analysis. Nevertheless, there is still a lack of gold standards for the
diagnosis of PJI (12, 13), because the clinical presentation of PJI is
often ambiguous (14), and classical inflammatory markers can be
misleading (15–17). In order to optimize the diagnostic process,
infection biomarkers with fast response and high sensitivity and
specificity for infection are needed (7).
In this context, TLR could be useful for PJI diagnosis. Indeed,
TLR expression has already been considered of relevance in dif-
ferent inflammatory conditions and infections (18), but so far the
potential diagnostic use of this molecule remains unexplored. For
this reason, in this study the serum levels of the two main TLRs
involved in bacterial infection, TLR2 and TLR4, weremeasured in
PJI patients and in nonseptic patients undergoing implant revi-
sion and were compared to classical inflammatory parameters,
such as C-reactive protein (CRP), and with the main inflamma-
tory cytokines, interleukin 1 (IL-1), IL-6, and tumor necrosis fac-
tor alpha (TNF-), in order to explore the potential use of TLR2
and TLR4 serum levels as novel diagnostic tools for PJI identifica-
tion.
Patient population was described in Table 1. We selected 32
patients undergoing revision of total hip or total knee joint arthro-
plasty and displaying prosthetic chronic infection for at least 6
months, as demonstrated by clinical and laboratory signs typical
of bone joint infection: swelling, erythema, joint pain, and secre-
tion of purulent material. Diagnosis of infection was confirmed
according to the criteria set forth by Spangehl et al. (19): at least
three positive results for (i) erythrocyte sedimentation rate, (ii)
C-reactive protein and aspiration, (iii) frozen section, or (iv) in-
traoperative culture. As a control, we selected 28 noninfected pa-
tients undergoing routine orthopedic surgery without any other
underlying disease or infection of inflammation and showing no
comorbid conditions that could affect the expression of TLR2 and
other markers, no antibiotic therapy in progress, and no diabetes
mellitus type 2 or obesity.
PJI and control patients werematched for age, sex, and severity
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TABLE 1 Patient clinical features
Characteristic
Value
Controls PJI patients
Amt of TLR (pg/ml) SD
TLR4 348.81 28.61 384.28 43.84
TLR2 171.04 34.36 504.19 64.96
Amt of inflammatory marker (pg/ml) SD
C-reactive protein 0.48 0.27 2.63 1.79
TNF- 1.78 0.51 6.70 1.94
IL-1 2.19 0.52 15.79 3.62
IL-6 1.822 0.75 11.2 3.86
No. of patients with:
Staphylococcus aureus (Gram positive) 11
Staphylococcus epidermis (Gram positive) 7
Staphylococcus xylosus (Gram positive) 1
Staphylococcus warneri (Gram positive) 1
Staphylococcus caprae (Gram positive) 1
Staphylococcus aureus (Gram positive) 1
Streptococcus anginosus (Gram positive) 1
Streptococcus agalactiae (Gram positive) 1
Enterococcus faecalis (Gram positive) 2
Corynebacterium striatum (Gram positive) 4
Klebsiella pneumonia (Gram negative) 1
Pasteurella multocida (Gram negative) 1
Staphylococcus aureus (Gram positive)/Acinetobacter
baumannii (Gram negative)
1
Staphiylococcus aureus (Gram positive)/Pseudomonas
aeruginosa (Gram negative)
1
No. of females and males 16 females, 12
males
16 females, 12
males
Mean age (yrs) SD 68 22 63 21
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of illness. Bloodwas drawn from all patients for serum separation,
aliquoted, and stored at80°C until further analysis.
CRP was measured using immunoturbidimetry on an auto-
mated biochemical analyzer (CRP-Latex assay; Olympus, Central
Valley, PA, USA).
Human IL-1, IL-6, and TNF- and TLR2 were measured in
serum using an enzyme-linked immunosorbent assay (ELISA)
sandwich duo set assay, according to themanufacturer’s protocols
(R&D Systems, Minneapolis, MN, USA). Human TLR4 serum
concentration was measured by ELISA sandwich assay according
to the manufacturer’s protocols (USCN LifeScience Inc., Wuhan,
Hubei, People’s Republic of China; catalog number E90753Hu).
TLR2 ELISA kit (DY2612; R&D Systems) was optimized for the
analysis of TLR2 in cell supernatants and serum.
For all the parameters analyzed, normality of distribution of
the three groups was verified by the Kolmogorov-Smirnov test for
normal distribution.
Statistical analysis was performed using a one-way analysis of
variance (ANOVA) test, and P values of 0.05 were considered
significant and P values of 0.005 were considered very signifi-
cant.
Linear regression analysis was performed between the different
groups of data, and the 95% confidence interval of the regression
line was calculated by using PRISM 3.0 software.
Surgical infection is due mainly to Staphylococcus aureus (20,
21), a Gram-positive bacterium recognized by TLR2 (22), while a
small amount is due to Gram-negative bacteria, bound by TLR4.
Accordingly, in infected patients, we observed 87.5% of Gram-
positive and only 12.5% of Gram-negative infection and, as a con-
sequence, a significant increase of TLR2 but not of TLR4 (Fig. 1).
TLR2 has been described to be crucial in joint infection (20), con-
tributing to the degenerative process and destructive arthropathy
after microbial joint infection (23), indicating that TLR2 expres-
sion strictly reflects the progression of the infection in the host. So
far, the alteration of TLR2 andTLR4has been evaluated only at the
gene expression level (24, 25), while the present work is the first, to
our knowledge, which measures the amount of circulating pro-
tein, making it suitable for routine clinical diagnosis. In order to
FIG 1 TLRs and inflammatory mediators. (A) Serum levels of TLR2 and TLR4 in prosthetic joint infection patients (gray bars) and noninfected patients
(white bars); (B) serum levels of inflammatory cytokines (IL-1, IL-6, and TNF-) in prosthetic joint infection patients (gray bars) and noninfected
patients (white bars); (C) serum levels of C-reactive protein in prosthetic joint infection patients (gray bars) and noninfected patients (white bars).
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evaluate TLR2 circulating levels as diagnostic tools, we compared
them with canonical markers of infection and inflammation.
TLR2 showed a strong positive correlationwith CRP (Fig. 1B), the
gold standard clinical marker of infection, which is increased in
PJI patients, indicating that the serum TLR2 molecule is able to
detect an inflammatory condition. Moreover, since TLR2mecha-
nism of action leads to an inflammatory response (3), we mea-
sured the circulating levels of the three main inflammatory cyto-
kines: IL-1 and TNF- for local inflammatory response and IL-6
for systemic response. Infected patients displayed a significant in-
crease of all the cytokines analyzed, in particular IL-6, previously
described to be a significant marker of PJI (16), and IL-1. In PJI
patients, TLR2 displayed a strong positive correlation with both
IL-6 and IL-1, which exert a protective role on the tissue in S.
aureus infection (26), confirming the importance of TLR2 in the
detection of PJI (Fig. 2). Given the small sample size of patient
groups, the results of this pilot study are preliminary, but taken
together, they indicate that serum TLR2 can be considered, in
association with canonical parameter of inflammation, a new po-
tential diagnostic marker of PJI.
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